PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The contrarian in me says that when everybody’s bullish about everything, it’s time to get a little cautious,’ says John ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

Pfizer’s top-selling breast cancer drug Ibrance also on list Drugmakers ... With list prices of about $1,000 a month, Novo’s treatments are among the biggest products in pharmaceutical history, ...

Revlimid, the big-selling ... produce “top-tier growth in the sector by the end of the decade," Boerner said. During an afternoon discussion with J.P. Morgan analyst Chris Schott, Pfizer CEO ...